PT-141 + Melanotan II: Two Melanocortin Agonists in One Vial
Also known as: PT-141 + Melanotan II · PT-141 + MT2 · Bremelanotide + Melanotan II
This is the one blend on this page where the pharmacology argues actively against the combination. PT-141 (bremelanotide) and Melanotan II are both melanocortin receptor agonists acting on an overlapping receptor family — PT-141 is in fact a metabolite of Melanotan II. Combining them is not adding two independent effects; it is pushing harder on largely the same pathway. Since the dose-limiting problems of that pathway are nausea, flushing and blood-pressure effects, stacking two agonists predictably compounds the side effects more reliably than the benefit. Educational only, not medical advice.
Why this is not two separate drugs
PT-141 is bremelanotide, which is a metabolite of Melanotan II — the two are chemically and pharmacologically closely related rather than distinct compounds that happen to be combined.
Both act on melanocortin receptors. Melanotan II is less selective and hits MC1R meaningfully, which is where the tanning and pigmentation effects come from, along with MC3R and MC4R. PT-141 is comparatively weighted toward the MC4R activity associated with the sexual-function effect, which is why it — and not Melanotan II — went through clinical development and reached approval for hypoactive sexual desire disorder in women.
So the honest framing is that Melanotan II is the broader, dirtier compound and PT-141 is the narrower one refined out of it. Putting them back together moves in the opposite direction from the development history.
The side-effect arithmetic
Nausea is the most common dose-limiting effect of melanocortin agonists and it is dose-dependent. Flushing is common. Transient blood-pressure increases are documented for bremelanotide, which is why its label carries a caution around uncontrolled hypertension and why it is not intended for daily use.
Two agonists on an overlapping receptor set means these effects add up, and the vial's fixed ratio means you cannot reduce one component to manage them. You can only reduce the whole dose, which reduces whatever benefit you were after too.
Melanotan II separately carries the pigmentation issue that has driven most of the clinical concern about it: darkening and change in existing moles and new nevi. That is the reason dermatologists object to it, and it is not something a blend dilutes away.
How to track PT-141 + Melanotan II in Stackeddd
If you use this, log blood pressure around dosing rather than only the effect you are after — transient increases are documented for bremelanotide, and it is the one measurable risk here that you can actually check at home.
Model it yourself · free, no account
Reconstitution Calculator
A blend is one reconstitution that sets the dose of every compound in the vial — get the water volume right once and every draw after it is correct.
Related compounds
Related reading: What peptides can you mix in the same syringe?
Frequently asked questions
Is combining PT-141 and Melanotan II useful?
The pharmacology argues against it. PT-141 is a metabolite of Melanotan II and both act on overlapping melanocortin receptors, so combining them pushes harder on largely the same pathway rather than adding independent effects. Since nausea, flushing and blood-pressure changes are the dose-limiting problems of that pathway, the side effects compound more reliably than the benefit.
What is the difference between PT-141 and Melanotan II?
Melanotan II is the broader, less selective compound — it hits MC1R, which produces the tanning and pigmentation effects, alongside MC3R and MC4R. PT-141 is weighted toward the MC4R activity linked to sexual function, which is why it was developed clinically and approved for hypoactive sexual desire disorder in women while Melanotan II was not.
What is the main concern with Melanotan II?
Pigmentation changes — darkening of existing moles and the appearance of new ones. That is the basis of most dermatological objection to it, and it is not reduced by being in a blend.
This is educational information, not medical advice. Doses and protocols above reflect published references and community practice — protocol decisions belong with your prescribing physician. Generic names used throughout. How this reference is built & how the AI is tested →
STACKEDDD
Track it instead of guessing.
Doses, reconstitution, bloodwork, and an AI coach grounded in your own data — free to start, on the App Store and Google Play.